Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Boehringer Ingelheim
Mallinckrodt
McKesson
Medtronic
Dow
Cantor Fitzgerald
Federal Trade Commission
Covington

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CIPRODEX

« Back to Dashboard

Clinical Trials for Ciprodex

Trial ID Title Status Sponsor Phase Summary
NCT00945802 FST-201 In The Treatment of Acute Otitis Externa Terminated Shire Phase 3 The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute otitis externa.
NCT00956748 N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media Not yet recruiting St. Paul's Hospital, Canada Phase 4 Chronic suppurative otitis media (CSOM) can be particularly difficult to treat as a number of patients do not respond to routine antibiotic or surgical treatments. The current treatment involves administering combination antibiotic anti-inflammatory ear drops such as Ciprodex (ciprofloxacin 0.3% / dexamethasone 0.1%). Although most patients experience a relief of symptoms, a fraction of patients remain refractory to treatment. Recent findings suggest that the addition of N-acetylcysteine (0.5-2%) to Ciprodex is a superior treatment for otitis media with effusion compared to the use of Ciprodex alone.
NCT00961675 FST-201 in the Treatment of Acute Otitis Externa Completed Shire Phase 3 The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa. This study will be conducted at one site, the LBJ Tropical Medical Center, Department of Otolaryngology, in Pago Pago, American Samoa.
NCT01027494 Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora Completed Alcon Research Phase 3 The purpose of this observational study was to evaluate the effects of a topical fluoroquinolone (antibiotic) instilled into the otic (ear) canal to treat Acute Otitis Media through Tympanostomy Tubes (AOMT) on selected bacterial species on the skin near the ear, in the nose, and in the throat.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ciprodex

Condition Name

Condition Name for Ciprodex
Intervention Trials
Acute Otitis Externa 3
Acute Otitis Media 2
Otitis Externa 2
Otorrhea 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ciprodex
Intervention Trials
Otitis 9
Otitis Media 5
Otitis Externa 5
Otorhinolaryngologic Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ciprodex

Trials by Country

Trials by Country for Ciprodex
Location Trials
United States 32
American Samoa 1
Canada 1
Puerto Rico 1
Israel 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ciprodex
Location Trials
Texas 3
North Carolina 3
Florida 3
Ohio 2
Arizona 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ciprodex

Clinical Trial Phase

Clinical Trial Phase for Ciprodex
Clinical Trial Phase Trials
Phase 4 2
Phase 3 6
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ciprodex
Clinical Trial Phase Trials
Terminated 4
Completed 3
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ciprodex

Sponsor Name

Sponsor Name for Ciprodex
Sponsor Trials
Shire 2
Par Pharmaceutical, Inc. 2
Novum Pharmaceutical Research Services 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ciprodex
Sponsor Trials
Industry 10
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
Julphar
Colorcon
Baxter
Federal Trade Commission
Fish and Richardson
US Army
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.